Journal of Biomedical Sciences

  • ISSN: 2254-609X
  • Journal h-index: 18
  • Journal CiteScore: 4.95
  • Journal Impact Factor: 4.78
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Mini Review - (2022) Volume 11, Issue 11

A Short Note on the Enhanced infectious diseases vaccines

Aaron Marta*
Genomics Research Centre, Academia Sinica, Taipei, 115, Taiwan
*Correspondence: Aaron Marta, Genomics Research Centre, Academia Sinica, Taipei, 115, Taiwan, Email:

Received: 01-Nov-2022, Manuscript No. IPJBS-22-13312; Editor assigned: 03-Nov-2022, Pre QC No. IPJBS-22-13312; Reviewed: 16-Nov-2022, QC No. IPJBS-22-13312; Revised: 21-Nov-2022, Manuscript No. IPJBS-22-13312; Published: 30-Nov-2022, DOI: 10.36648/2254- 609X.11.11.92


The best way to avoid getting the influenza virus is to get vaccinated. In any case, flow occasional flu antibodies are just defensive against firmly paired coursing strains. Our efforts frequently result in mismatches and low vaccine effectiveness, despite extensive monitoring and annual reformulation. As a result, we are still one step behind the rapidly evolving virus. Fortunately, numerous next-generation influenza vaccines are currently in development, making use of a variety of cuttingedge methods to speed up production and broaden protection. The vaccine manufacturing practices that are currently in use, the most recent advancements in influenza vaccine research, and any potential obstacles that need to be overcome are all covered in this overview. The advantages of removing the glycan shield from influenza surface antigens in order to increase vaccine immunogenicity and the potential role that glycol engineering might play in the development of an influenza vaccine are given particular attention. From an industry perspective, the possibility of developing these novel influenza vaccine candidates in the future is discussed.


Influenza Virus; Glycoengineering; Vaccine


Each year, seasonal influenza outbreaks result in 290,000 to 650,000 respiratory deaths and 3 to 5 million severe cases [1, 2]. The Orthomyxoviridae are a group of enveloped viruses whose genome consists of six to eight segments of negative-sense singlestranded RNA. Among them are four influenza virus genera: C, D, A, B, and C [3]. Annual human flu outbreaks are primarily caused by influenza A and B, with influenza A further subdivided into hemagglutinin (HA) and neuraminidase (NA) surface glycoprotein subtypes. The H1N1 and H3N2 subtypes, which co-circulate in the human population, are currently the most well-known of the 18 HA subtypes (H1-H18) and 11 NA subtypes (N1-N11). Influenza B has diverged into the Yamagata and Victoria lineages based on antigenicity since the 1970s, with little or no serum crossreactivity. Influenza C infections only cause mild flu symptoms in children, whereas influenza D is not known to infect humans. This is in contrast to the severity and potential for an epidemic of influenza A and B. The influenza virus uses two methods to evade detection, resulting in recurrent influenza epidemics in populations with established immunity: antigenic float and antigenic shift. Antigenic drift is the gradual accumulation of point mutations on the HA and NA surface glycoproteins of the influenza virus, which is caused by the high error rates of the virus's RNA-dependent RNA polymerase (RdRP) (estimated at 1.5 10 5 per nucleotide per replication). Transformations that permit the infection to sidestep the host safe framework are decidedly chosen for and become fixed, bringing about the ascent of new strains that are antigenically not the same as what the host was immunized against. The reassortment of gene segments among various strains infecting the same host, resulting in a total change in antigenicity, is the second escape mechanism, antigenic shift [4, 5]. The most recent example of this is the 2009 swine-origin H1N1 that included segments from classical swine H1N1, Eurasian swine H1N1, and a triple reassortant from 1998. Antigenic shift have historically been associated with influenza pandemics. Cross-immunity-mediated competition between antigenically similar strains follows the rise of new strains caused by antigenic drift and shift. This leads to the progressive replacement of existing strains with new variants. Unfortunately, the current seasonal influenza vaccines are strain-specific and only cover a very small portion of the population. As circulating strains change constantly over time, thorough surveillance, precise predictions, and annual vaccination are required.


The WHO's Global Influenza Surveillance and Response System (GISRS), which compiles year-round data from hundreds of national influenza centers worldwide and issues vaccine formulation recommendations for each forthcoming flu season , is in charge of overseeing this endeavor. Vaccination protects healthy adults younger than 65 years old by 70–90 percent when vaccine strains are well-matched to circulating strains and reduces hospitalizations by 30–70 percent in the elderly and those with chronic illnesses [6]. However, the vaccine effectiveness (VE) tends to be significantly lower in years when there is a mismatch between the vaccine and circulating strains. A universal influenza vaccine that uses carbohydrate design to elicit broadly neutralizing antibodies (bnAbs) that target the influenza HA glycoprotein may be able to contribute to the future of influenza prevention, as we discuss a number of issues with the seasonal flu vaccine. Even though the first commercially available influenza vaccine was available in 1945, influenza outbreaks are still a major public health concern today. The pharmaceutical industry, researchers, and health authorities must collaborate to improve influenza vaccine effectiveness. The adaptation process of cultivating a human virus in avian tissue, where adaptive mutations may accumulate and potentially alter the strain's antigenicity, is a second disadvantage of using an egg-based platform [7]. By binding to sialic acids on the surface of the host cells, HA is not only the primary facilitator of influenza virus entry but also the primary target for neutralizing antibodies. Typically found on epithelial cells in the human upper respiratory tract, human influenza HA preferentially binds to 2,6-linked sialic acids. However, vaccine strains are injected into the allantoic cavity of embryonated chicken eggs, which only contain -2, 3 linkages, in egg-based production. This develops into a selective pressure over time, resulting in mutations and antigenic changes on the HA receptor binding site as well as the acquisition or total shift in receptor specificity. During the 2016–2017 flu season, eggadapted vaccine strains were discovered to lack a glycosylation site (T160, H3 numbering) on H3N2 HA antigenic site B, one of the five major antigenic sites that induce neutralizing antibodies. This provides a recent illustration of this phenomenon. The egg-based platform's dependence on a consistent supply of embrocated eggs is a third concern. When there is a sudden increase in demand, like during a pandemic, this egg supply can be overwhelmed. LAIV is created by joining the HA and NA of right now circling strains with the inside proteins of a weakened cold-adjusted strain. As a result, a vaccine virus that can be given intravenously and has some limited ability to replicate in the human upper respiratory tract is produced. In addition to eliciting a robust antibody response, LAIV has also been reported to elicit cell-mediated immunity, local mucosal immunity, and the entire influenza replication cycle at the site of infection. In clinical trials, LAIV has been found to be more effective than IIV in children but to a lesser extent than IIV in adults.

As of late be that as it may, the need of powerful replication in human respiratory tissue has arisen as an area of concern. Despite the fact that this phenomenon was not observed in Europe or Canada, the US Advisory Committee on Immunization Practices (ACIP) recommended against LAIV from 2016 to 2018 due to the low efficacy of the H1N1 component. The reason for this lack of effectiveness is still unknown, but some possibilities include the H1N1 pandemic strain's inherent lower replication in host tissue, strong cross-reactive antibodies from previous seasons preventing virus replication, and viral interference of tetravalent vaccine strains resulting in reduced virus shedding for the weakest strain. Following a change in the H1N1 vaccine component in 2018, ACIP resumed recommendation for LAIV. Second, LAIV is plagued by many of the same issues as egg-based IIV because it is also produced in embrocated chicken eggs. Due to low yields in two strains, AstraZeneca's LAIV product FluMist experienced manufacturing issues in 2019 and saw a decrease in worldwide shipments.


The development of influenza vaccines has shown that cell-based vaccines are gradually replacing traditional egg-based vaccines. With the plenty of cutting edge immunizations at present a work in progress, WHO anticipates that a general flu An immunization should be in cutting edge clinical preliminaries as soon as 2027 [8]. The most significant obstacle to regulatory approval remains demonstrating clinical safety and efficacy in a human population, despite the fact that many candidates have demonstrated promising results in preclinical studies. Through enzymatic trimming of N-glycans, our group pioneered the method of exposing previously shielded conserved epitopes on the HA. A hypothetical trivalent or tetravalent monoglycosylated vaccine containing the three influenza subtypes (H1, H3, and influenza B) circulating in the human population would be, for all intents and purposes, a universal flu vaccine because this method has been shown to elicit cross-neutralizing antibodies against antigenically diverse strains of influenza viruses within a subtype.We believe that the monoglycosylated split virus vaccine strategy has three distinct advantages over other approaches for developing new drugs: Due to the rapid mutation rate of the influenza virus, using only a single conserved epitope as the antigenic target for a universal vaccine runs the risk of producing escape mutants [9, 10]. The monoglycosylated split vaccine provides multiple conserved epitopes for immune recognition. The idea that monoglycosylated split virus vaccine induces more stemspecific antibodies directed against conserved epitopes on the HA stem has only been demonstrated in our previous research. Theoretically, however, removing oligosaccharides from each HA N-glycosylation site would expose multiple conserved epitopes, leading to a multifaceted immune response and a higher evolutionary barrier for the generation of escape mutants. NA is an additional influenza glycoprotein that might benefit from the monoglycosylation process. Glycans from both HA and NA would be removed during the manufacturing of a monoglycosylated split virus vaccine, potentially increasing the number of anti-NA antibodies that hinder virus development, disease progression, and severity of symptoms.



Conflict of Interest



  1. Aach RD, Stevens CE, Hollinger FB, Mosley JW, Peterson DA, et al. (1991) Hepatitis C virus infection in post-transfusion hepatitis An analysis with first-and second-generation assays. N Engl J Med 325: 1325-1329.
  2. Google Scholar, Crossref, Indexed at

  3. Yee T, Griffioen A, Sabin C, Dusheiko G, Lee CJG, et al. (2000) The natural history of HCV in a cohort of haemophilic patients in fected between 1961 and 1985. J Thromb Haemost 47: 845-851.
  4. Google Scholar, Crossref, Indexed at

  5. Wong T, Recht MJD (2011) Current options and new developments in the treatment of haemophilia. Biologics 71: 305-220.
  6. Google Scholar, Crossref, Indexed at

  7. Roberts HR KN, Escobar MA (2010) Hemophilia A and haemophilia B. In: Kaushansky K, Lichtman M, Beutler E, et al, eds. Williams Hematology 2009-2030.
  8. Google Scholar, Crossref     

  9. Marrazzo JM, del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, et al. (2014) HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312: 390-409.
  10. Google Scholar, Crossref, Indexed at 

  11. Sterne JA, Costagliola D, de Wolf F, Phillips AN, Funk MJ, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 373: 1352-1363.
  12. Google Scholar, Crossref, Indexed at

  13. Beard J, Feeley F, Rosen S (2009) Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review. AIDS Care 21: 1343-1356.
  14. Google Scholar, Crossref, Indexed at

  15. Attia S, Egger M, Müller M, Zwahlen M, Low N, et al. (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397–404.
  16. Google Scholar, Crossref, Indexed at

  17. Orrell C (2005) Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS Rep 2: 171-176.
  18. Google Scholar, Crossref, Indexed at

  19. Malta M, Strathdee SA, Magnanini MM, Bastos FI (2008) Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 103: 1242-1257.
  20. Google Scholar, Crossref, Indexed at

Citation: Marta A (2022) A Short Note on the Enhanced Infectious Diseases Vaccines. J Biomed Sci, Vol. 11 No. 11: 92